PRECISION BIOSCIENCES INC — Director's Dealing 2019

Mar 29, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PRECISION BIOSCIENCES INC (DTIL)
CIK: 0001357874
Period of Report: 2019-03-27

Reporting Person: YAO TONY DUNG LING (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-27	Convertible Promissory Note	$13.60	J		Acquired		Common Stock (36946)	Indirect

Footnotes

F1: On March 1, 2019, ArrowMark Life Science Fund, LP (the "ArrowMark Fund") acquired a convertible promissory note in the principal amount of $500,000 (the "2019 Note") from Precision BioSciences, Inc. (the "Issuer"). In connection with the pricing of the Issuer's initial public offering on March 27, 2019 (the "IPO"), the conversion price of the 2019 Note became fixed at 85% of the price per share in the IPO, and the 2019 Note became automatically convertible into shares of the Issuer's common stock at the closing of the IPO.

F2: The 2019 Note is held of record by the ArrowMark Fund. ArrowMark Colorado Holdings LLC ("ArrowMark Colorado") is an investment advisor to the ArrowMark Fund. The reporting person is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the shares held by the ArrowMark Fund. The reporting person disclaims beneficial ownership of the 2019 Note, except to the extent of any pecuniary interest therein.